Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 6, 2025
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
GlobeNewswire
·
May 6, 2025
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue …
Amwell makes grant to new employee under inducement plan
GlobeNewswire
·
May 6, 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered …
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
GlobeNewswire
·
May 6, 2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to …
InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025
GlobeNewswire
·
May 6, 2025
DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All- …
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
GlobeNewswire
·
May 6, 2025
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations, underscoring the strength of Clover’ …
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
GlobeNewswire
·
May 6, 2025
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its …
WW International, Inc. Announces First Quarter 2025 Results
GlobeNewswire
·
May 6, 2025
Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical Subscribers Revenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 million, up 57.1% vs. prior year period …
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients …
Voyager Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ …
Lantheus Announces Sale of SPECT Business to SHINE Technologies
GlobeNewswire
·
May 6, 2025
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus …
Standard BioTools Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 6, 2025
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an …
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
GlobeNewswire
·
May 6, 2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation …
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 6, 2025
WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic …
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “The completion of our BLA submission for …
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
May 6, 2025
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million Reaffirm 2025 Financial Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and …
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
GlobeNewswire
·
May 6, 2025
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company …
United Fire Group, Inc. reports first quarter 2025 results
GlobeNewswire
·
May 6, 2025
First quarter net income of $0.67 per diluted share and adjusted operating income of $0.70 per diluted share First quarter 2025 highlights compared to first quarter 2024, unless otherwise noted:(1) Net income increased 31% to $17.7 million. Net investment …
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments …